Copley Gets a New Life
After a few volatile years, Copley Pharmaceutical has a new management team, which is gearing up the generics company for growth. Hoechst, which owns 51% of Copley, has said it wants to get out of the generics business and is letting the new management decide on an exit strategy. New CEO Daniel Korpolinski (previously head of CoCensys), believes that Copley's relationships with top national drug store chains remain strong and will help its revival.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.